Recent studies employing Gas6 neutralizing antibodies, GMAB1 and GMAB2, shown to decrease tumor growth in the pancreatic ductal carcinoma by blocking autocrine Gas6-Axl signaling clearly support the rationale to target Gas6 [78]. This evidence concerns the gene GAS6 and pancreatic ductal adenocarcinoma.